Connection Between Epigenome, Selective Mutability, Evolution, and Human Disease
Li, Harris et al., PLoS Genetics
Researchers at the Baylor College of Medicine and elsewhere propose a "connection between the epigenome, selective mutability, evolution, and human disease" based on the findings of their study on associations of structural mutability with germline DNA methylation and with non-allelic homologous recombination mediated by low-copy repeats. "Combined evidence from four human sperm methylome maps, human genome evolution, structural polymorphisms in the human population, and previous genomic and disease studies consistently points to a strong association of germline hypomethylation and genomic instability," the Baylor-led team writes.
A Conversation with the American Museum of Natural History's George Amato
The American Museum of Natural History's George Amato, director of the museum's Sackler Institute for Comparative Genomics, discusses conservation and "landscape" genetics, his PLoS One paper on the use of DNA barcoding to detect illegal bushmeat in New York-area airports, and more.
BioArray News editor Justin Petrone sat down with Shashikant Kulkarni, an associate professor at Washington University School of Medicine at St. Louis, to discuss chromosomal microarrary analysis in the clinic, SNP arrays versus CGH platforms for post-natal testing, and more.
Miragen Therapeutics' Eva van Rooij
Miragen Therapeutics' Eva van Rooij discusses microRNA-based therapeutics, the challenges associated with chronic microRNA knockdown, therapeutic microRNA antagonists, and more.
A Conversation with CeGaT's Saskia Biskup
In this video, Julia Karow, Editor of Clinical Sequencing News, interviews Saskia Biskup, CEO of the Center for Genomics and Transcriptomics, or CeGaT, at the company's headquarters in Tübingen, Germany.
In this video, Illumina's CLIA laboratory manager Suneer Jain gives InSequence and Clinical Sequencing News Editor Monica Heger a tour of Illumina's CLIA lab at the company's San Diego headquarters.
Q&A with Agendia CEO David Macdonald
Agendia CEO David Macdonald stopped by GenomeWeb's office in New York City and responded to questions from Turna Ray, editor of Pharmacogenomics Reporter, about his company's MammaPrint breast cancer recurrence test and more.
A Conversation with Robert Chalkley at ABRF
In this video, Adam Bonislawski, editor of ProteoMonitor, caught up with UCSF's Robert Chalkley at the recent Association of Biomolecular Resource Facilities meeting in Orlando, Fl. Chalkley, who is also chair of ABRF's Proteomic Informatics Research Group, discusses the challenge at this year's meeting — identifying post-translationally modified peptides in a complex background — and more.
Collaborative Effort Targets Alzheimer's Disease
We dropped by the Feinstein Institute for Medical Research in Manhasset, New York, for a conversation with Peter Davies, director of the Litwin-Zucker Center for the Study of Alzheimer's Disease and Memory Disorders. Davies is heading up a collaboration between the Feinstein Institute, the New York Genome Center, and Illumina that aims to uncover the genetic basis of Alzheimer's disease.
In this video, we sat down with Randall Nelson, research professor at Arizona State University's Biodesign Institute, at the Mass Spectrometry: Applications to the Clinical Laboratory 2012 meeting in San Diego. Nelson speaks about mass spectrometry immunoassay (MSIA) technology and protein heterogeneity, the challenges associated with moving mass spec into the clinic, and more.
Leigh Anderson at MSACL 2012 Part II
This is part two of a conversation with Leigh Anderson, CEO of SISCAPA Assay Technologies, at the Mass Spectrometry Applications to the Clinical Laboratory 2012 meeting in San Diego, California.
Leigh Anderson at MSACL 2012 Part I
This is part one of a conversation with Leigh Anderson, CEO of SISCAPA Assay Technologies, at the Mass Spectrometry Applications to the Clinical Laboratory 2012 meeting in San Diego, California.
This video from AGBT 2012 includes comments from Washington University's Elaine Mardis and Baylor College of Medicine's Donna Muzny — among others — on clinical applications of emerging sequencing technologies, desktop sequencing, and more.
We caught up with Harry Glorikian, founder and managing partner at Scientia Advisors, at this year's Tri-Con 2012 in San Francisco, California. Glorikian provides his views on current challenges for molecular diagnostics developers, sequencing in the clinic, clinical decision support systems, and more.